This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated September 2026 quarter revenue up 36.3%, profit after tax up 81.5% vs September 2025
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.8 pts more than Nifty Microcap 250 and 11.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated quarter ended 30 September 2026: revenue from operations rose 36.3% to Rs 2,603.48 crore and profit after tax rose 81.5% to Rs 335.17 crore, versus Rs 1,910.15 crore and Rs 184.71 crore in September 2025. EBITDA margin increased to 22.21% from 17.02%. Consolidated half-year: revenue Rs 4,753.25 crore and profit after tax Rs 508.23 crore, versus Rs 3,620.87 crore and Rs 339.09 crore. Unaudited results had an unqualified review.
Positive for shareholders: strong revenue and profit growth with wider margins may support the stock; low leverage limits financial risk.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹2,603 Cr | ₹1,910 Cr | +36.3% |
| Operating profit | ₹424.2 Cr | ₹215.4 Cr | +96.9% |
| Profit after tax | ₹333.9 Cr | ₹183.7 Cr | +81.8% |
| EBITDA margin | 21.6% | 16.5% | +5.1 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.